Search on our data base

Filter your search

  • Product

  • Resource type

  • Application Areas

  • Therapeutic Areas

  • Reset filters
Search results13
Flyer PDF
Immuno-oncology research – AltaZ
Flyer PDF
Virology research – AtlaZ
Application note PDF
GPCRs – Profiling the pharmacology of GPCRs by time-resolved impedance measurements
AtlaZ Application note

This Application Note demonstrates the in vitro characterization of GPCR pharmacology, covering agonist and antagonist mode of action, dose-response relationships, and the involvement of signal transduction cascades. Experimentally,
cells expressing H1R or Y4R are cultured on planar gold-film electrodes integrated into standard cell culture dishes.

Application Note PDF
Hepatocytes – “Comprehensive impedance-based hepatotoxicity assay for metabolically active iPSC-derived hepatocytes”
CardioExcyte 96, AtlaZ Application Note: Cells were kindly provided by FUJIFILM CellularDynamics, FCDI

Hepatotoxicity and drug-induced liver injury (DILI) are leading reasons for drug failure to market, leading to approximately 18% of market withdrawals of drugs in the last decade.
Additionally, only half of drugs with a potential to induce hepatotoxicity are actually identified during preclinical animal studies. This highlights the importance of generating more
advanced cell-based models and experimental strategies to enhance the predictivity of these assays. Current existing in vitro models employed to predict DILI mostly focus on
hepatocytes, though primary hepatocytes do not maintain their phenotype. iCell® Hepatocytes 2.0 (FUJIFILM Cellular Dynamics, FCDI) are human iPSC-derived cells with a
wide variety of basic and functional characteristics which make them amenable to applications such as compound mediated ADME-T and DILI toxicity. In addition to displaying
characteristic hepatocyte morphology, (i.e., polygonal shape, polynucleation and formation of bile canalicular channels), these cells also express liver cell markers, including albumin,
A1AT, and HNF4a, and exhibit basic and induced P450 functions, as observed in primary human hepatocytes. iCell® Hepatocytes 2.0 maintain morphology, marker expression,
and metabolic function in culture over a longer time frame compared to primary human hepatocytes, rendering these cells useful for investigations of acute and chronic DILI responses in a 2D culture system using impedance. Combining these cells with the planar gold-film electrodes on the impedance systems reveal alterations in confluency, cell contact (morphological shape) and conductivity of adherent cells, thereby providing a measure of toxicity. Dose-dependent harmful effects of drugs could be evaluated over time in a functional 2D cell-based model without the need for 3D spheroid formation.

Application Note PDF
Cardiotox., cardio-oncology – “Chronic cardiotoxicity study on H9C2 cells using HESI stem cell working group reference compounds”
AtlaZ application note
Poster PDF
2023 – AtlaZ as a High-Throughput System for Advanced Functional Cell Analysis to Develop Immunotherapies
AtlaZ Poster
Application Note PDF
CAR T, Cancer – “CAR T cell-mediated killing of cancer cells”
AtlaZ application note

The US Food and Drug Administration has approved a number of chimeric antigen receptor (CAR) T-cell therapies. Due to the nature of CAR T cells as “living drugs”, they display a unique toxicity profile. As CAR T-cell therapy is extending towards multiple diseases and being broadly employed in hematology and oncology, being able to reliably predict treatment efficacy and a quantification of responses are of high relevance. Furthermore, for continued breakthroughs, novel CAR designs are needed. This includes different antigenbinding domains such as antigen-ligand binding partners and variable lymphocyte receptors (1). Now, after amazing advances for treating blook cancers, CAR T cell therapy is showing promise for solid tumors.

In general, identifying T cells that kill cancer cells in vivo is critical to the development of successful cell therapies. The label-free AtlaZ immune cell killing assay can be used to measure rate of killing at Effector:Target (E:T) ratios to predict in vivo activity. In order to gain a deeper understanding of cancer cells, real-time and continuous monitoring is necessary to access kinetic and phenotypic information. Such monitoring captures also unique toxicity profiles of CAR T cells.

Product video
2023 – AtlaZ accelerates cellular research
AtlaZ accelerates cellular research by enabling the investigation of a large variety of effects in cells over time.

AtlaZ accelerates cellular research by enabling the investigation of a large variety of effects in cells over time. It offers label-free and real-time monitoring capabilities. It can simultaneously or independently record data from up to six 96-well plates.

Case study PDF
Immune cells- “Immune cell – mediated killing of tumor cells with the AtlaZ platform”
Application Note PDF
TEER – “Monitoring cell – attachment and tight junctions in the same assay”
AtlaZ application note

The numerous different cell types in the human body are greatly specialized and often require a conjunctive action of a population of cells, for example in tissues. Cells are interconnected via cell junctions, multiprotein complexes found in the cell membrane of animal cells, and such cell junctions allow for a mechanical, chemical or electrical transmission of signals. These junctions can be subdivided into (I) tight junctions, (II) anchoring junctions or (III) gap junctions. Defects in cell–cell junctions give rise to a wide range of tissue abnormalities that disrupt homeostasis and are common in genetic abnormalities and cancers (1). The so-called tight junctions form the barrier in endothelial and epithelial cells. Classical transepithelial electrical resistance measurements are performed using microelectrodes, where trans- and para-cellular conductivities can be calculated (2).
Here the cells are grown on a porous filter membrane which is placed between two fluid compartments. Flux of solutes from one compartment to the other must pass the interfacial cell
layer then, and this is determined by the functional properties of the tight junctions.

Application Note PDF
Cancer, Immuno-oncology – “Immune cell-mediated killing of A549 cancer target cells in real-time”
AtlaZ application note

Cancer remains one of the leading causes of death, with, according to the World Health Organisation (WHO), around 10 million people dying due to the disease in 2020 (1). Chemo and
radio-therapy are still the dominant treatment types, but advancing therapies such as immuno-therapy have emerged as tools to fight against the disease. In general, identifying T cells that kill cancer cells in vivo is critical to the development of successful cell therapies. The label-free AtlaZ immune cell killing assay can be used to measure rate of killing at Effector : Target (E:T) ratios to predict in vivo activity. In order to gain a deeper understanding of cancer cells, real-time and continuous monitoring is necessary to access kinetic and phenotypic information.

The platform used here, AtlaZ, is a quantitative live-cell analysis system and allows for cellular research on cell adhesion and proliferation, cytotoxicity, GPCR, morphology and
barrier function, label-free and in real-time. Recordings can be performed in up to six 96-well plates simultaneously or independently. Electrical impedance spectroscopy (2,3) as
the methodology behind the AtlaZ system, in combination with the throughput of 6 x 96-wells allows for a so far unmet quantity and richness of information which can be gained from cells.

Product sheet PDF
AtlaZ – Product Sheet
Product Sheet PDF
Cell Analytics – Interactive Brochure

How can we help you?

Contact our specialist Dr. Sonja Stölzle-Feix (Director Scientific Affairs and Product Manager of Cell analytics systems). Sonja is delighted to help you:

Sonja@nanion.de
or call: +49 89 2190 95-075
or connect via LinkedIn